[go: up one dir, main page]

MX2019003368A - Agentes anticancerigenos y preparacion de los mismos. - Google Patents

Agentes anticancerigenos y preparacion de los mismos.

Info

Publication number
MX2019003368A
MX2019003368A MX2019003368A MX2019003368A MX2019003368A MX 2019003368 A MX2019003368 A MX 2019003368A MX 2019003368 A MX2019003368 A MX 2019003368A MX 2019003368 A MX2019003368 A MX 2019003368A MX 2019003368 A MX2019003368 A MX 2019003368A
Authority
MX
Mexico
Prior art keywords
preparation
cancer agents
compounds
methods
cancer
Prior art date
Application number
MX2019003368A
Other languages
English (en)
Other versions
MX394670B (es
Inventor
K Ghosh Arun
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Publication of MX2019003368A publication Critical patent/MX2019003368A/es
Publication of MX394670B publication Critical patent/MX394670B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Las modalidades proporcionan, entre otros compuestos, una familia de compuestos que pueden usarse como agentes terapéuticos anticancerígenos, métodos para usar dichos compuestos para tratar el cáncer y métodos para preparar dichos compuestos.
MX2019003368A 2016-09-23 2017-09-22 Agentes anticancerigenos y preparacion de los mismos. MX394670B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662398783P 2016-09-23 2016-09-23
PCT/US2017/052967 WO2018057897A1 (en) 2016-09-23 2017-09-22 Anti-cancer agents and preparation thereof

Publications (2)

Publication Number Publication Date
MX2019003368A true MX2019003368A (es) 2019-09-16
MX394670B MX394670B (es) 2025-03-11

Family

ID=61690726

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003368A MX394670B (es) 2016-09-23 2017-09-22 Agentes anticancerigenos y preparacion de los mismos.

Country Status (14)

Country Link
US (2) US10858371B2 (es)
EP (1) EP3515492B1 (es)
JP (1) JP7111722B2 (es)
KR (1) KR102646702B1 (es)
CN (1) CN109862916A (es)
AU (1) AU2017331260B2 (es)
BR (1) BR112019005885A2 (es)
CA (1) CA3037883A1 (es)
DK (1) DK3515492T3 (es)
IL (1) IL265521B2 (es)
MA (1) MA46291A (es)
MX (1) MX394670B (es)
RU (1) RU2019111768A (es)
WO (1) WO2018057897A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10858371B2 (en) 2016-09-23 2020-12-08 Purdue Research Foundation Anti-cancer agents and preparation thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901464A (fr) 1943-01-23 1945-07-27 Boehringer & Soehne Gmbh Procédé d'obtention de vanilline
US7825267B2 (en) 2006-09-08 2010-11-02 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Synthesis of FR901464 and analogs with antitumor activity
WO2009031999A1 (en) 2007-09-07 2009-03-12 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Fr901464 and analogs with antitumor activity and method for their preparation
CN101417934B (zh) * 2007-10-24 2012-04-18 国鼎生物科技股份有限公司 分离自牛樟芝萃取物的化合物
AU2009225877B2 (en) 2008-03-18 2014-11-20 Genentech, Inc. Combinations of an anti-HER2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
US8969405B2 (en) 2008-06-21 2015-03-03 St. Jude Children's Research Hospital Anticancer compounds and methods of making and using same
WO2013130882A1 (en) * 2012-02-28 2013-09-06 Fred Hutchinson Cancer Research Center Compositions and methods for treating cancer
PL2917195T3 (pl) * 2012-11-05 2018-04-30 Pfizer Inc. Analogi spliceostatyny
US9771377B2 (en) 2012-12-21 2017-09-26 University of Pittsburgh—of the Commonwealth System of Higher Education Synthesis of FR901464 and analogs with antitumor activity
US20140274979A1 (en) 2013-03-13 2014-09-18 Golden Biotechnology Corporation Method for the treatment of fatty liver disease
CA2955059A1 (en) 2013-07-15 2015-01-22 Bettina PRONETH Spiroquinoxaline derivatives as inhibitors of non-apoptotic regulated cell-death
KR102092569B1 (ko) * 2013-09-17 2020-03-25 엘지디스플레이 주식회사 터치 스크린 일체형 디스플레이 장치와 이의 구동 방법
EP3071563B1 (en) 2013-11-19 2023-04-19 Purdue Research Foundation Anti-cancer agents and preparation thereof
WO2017214423A2 (en) * 2016-06-08 2017-12-14 William Marsh Rice University Derivatives of thailanstatin a, methods of treatment and methods of synthesis thereof
EP3515492B1 (en) 2016-09-23 2023-07-26 Purdue Research Foundation Anti-cancer agents and preparation thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10858371B2 (en) 2016-09-23 2020-12-08 Purdue Research Foundation Anti-cancer agents and preparation thereof

Also Published As

Publication number Publication date
US20210395265A1 (en) 2021-12-23
AU2017331260A1 (en) 2019-05-16
JP2019529563A (ja) 2019-10-17
WO2018057897A1 (en) 2018-03-29
RU2019111768A3 (es) 2020-11-24
CN109862916A (zh) 2019-06-07
BR112019005885A2 (pt) 2020-06-02
JP7111722B2 (ja) 2022-08-02
EP3515492A1 (en) 2019-07-31
IL265521B1 (en) 2024-05-01
EP3515492A4 (en) 2020-04-08
EP3515492B1 (en) 2023-07-26
CA3037883A1 (en) 2018-03-29
US11851441B2 (en) 2023-12-26
AU2017331260B2 (en) 2024-11-07
MA46291A (fr) 2019-07-31
DK3515492T3 (da) 2023-08-28
KR20190077340A (ko) 2019-07-03
RU2019111768A (ru) 2020-10-23
IL265521A (en) 2019-05-30
IL265521B2 (en) 2024-09-01
KR102646702B1 (ko) 2024-03-11
US20190218228A1 (en) 2019-07-18
MX394670B (es) 2025-03-11
US10858371B2 (en) 2020-12-08

Similar Documents

Publication Publication Date Title
ZA202004557B (en) Modulatory polynucleotides
PH12020550901A1 (en) Macrocyclic compounds for treating disease
PH12018500380A1 (en) Anti-dll3 antibody drug conjugates and methods of use
PH12016500953A1 (en) Tricyclic compounds as anticancer agents
EP4302835A3 (en) Methods of treating ovarian cancer
MX2019001125A (es) Inhibidores de cinasa macrociclica.
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
PH12016501898B1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
MA39906A (fr) Polythérapies pour le traitement du cancer
PH12017500406A1 (en) Novel anti-mfi2 antibodies and methods of use
MX2016004570A (es) Uso de inhibidores del bromodominio de cbp/ep300 para la inmunoterapia del cáncer.
MX2023011187A (es) Metodos para tratar el cancer de prostata.
MX2018006249A (es) Nuevos anticuerpos anti-emr2 y metodos de uso.
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
PH12016500967A1 (en) Functionalised and substituted indoles as anti-cancer agents
MX379271B (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cáncer.
MX377593B (es) Composiciones para usar en el tratamiento de cáncer renal.
MX2017017124A (es) 6-amino-quinolin-3-carbonitrilos como moduladores de cancer osaka tiroides (cot).
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
SG10201900564WA (en) Methods for treating cancer
PH12017500459A1 (en) Azetidinyloxyphenylpyrrolidine compounds
MX2018007817A (es) Nuevos anticuerpos anti-mmp16 y metodos para su uso.
MX2018007517A (es) Compuestos triciclicos y composiciones como inhibidores de quinasa.
EP3549582A3 (en) Novel capsazepine analogs for the treatment of cancer and other proliferative diseases